SCHEMBL497654

SCHEMBL497654

CC(=O)Nc1cc(-c2ccccc2)c2cc(Cl)ccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.52
ADORA3 P0DMS8 3/20 0.51
ADORA1 P30542 2/20 0.51
ADORA2B P29275 1/20 0.51
ADORA2A P29274 1/20 0.51
AURKA O14965 1/20 0.51
AURKB Q96GD4 1/20 0.51
LTB4R Q15722 1/20 0.49
FABP3 P05413 3/20 0.49
FABP4 P15090 3/20 0.49
DYRK1A Q13627 1/20 0.49
FSCN1 Q16658 1/20 0.49
PLA2G2A P14555 1/20 0.48
ACACA Q13085 1/20 0.47
ELANE P08246 1/20 0.47
DHODH Q02127 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
FABP5 Q01469 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9092428 0.96 MAPK1 (0.49) MAPK1ADORA3ADORA1ADORA2BADORA2A
SCHEMBL497310 0.84 KDM4E (0.52) ADORA3DYRK1AFSCN1ELANEMEN1
SCHEMBL29074154 0.83 MAPK1 (0.60) MAPK1ADORA1AURKAAURKBLTB4R
SCHEMBL9881006 0.82 MAPK1 (0.53) MAPK1AURKAAURKBLTB4RFABP3
SCHEMBL11822896 0.80 ALDH1A1 (0.61) MAPK1ADORA3ADORA2AAURKAAURKB
SCHEMBL4659606 0.79 ADORA1 (0.52) ADORA3ADORA1ADORA2BADORA2ADHODH
SCHEMBL28494527 0.77 PLA2G2A (0.59) MAPK1AURKAAURKBLTB4RFABP3
SCHEMBL28156610 0.77 MAPK1 (0.51) MAPK1AURKAAURKBLTB4RFABP3
SCHEMBL28883104 0.75 MAPK1 (0.61) MAPK1ADORA1AURKAAURKBLTB4R
SCHEMBL11826284 0.75 MAPK1 (0.65) MAPK1ADORA1AURKAAURKBLTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999112-B1 SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM SANOFI SA (FR) 2015-04-22 EP disclosed
US-8106204-B2 Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use SANOFI-AVENTIS (FR) 2012-01-31 US disclosed
US-20090118329-A1 Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use SANOFI-AVENTIS (FR) 2009-05-07 US disclosed
CN-101395137-A Substituted 2-amino-4-phenyl-dhydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them SANOFI AVENTIS (FR) 2009-03-25 CN disclosed
EP-1999112-A2 SUBSTITUTED 2-AMINO-4-PHENYL-D HYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM Sanofi-Aventis (FR) 2008-12-10 EP disclosed
WO-2007107246-A2 SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM SANOFI-AVENTIS (DE) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118329-A1 Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use NHERF1, SLC10A1, SLC9A3 MAPK1 2418/4885ADORA3 168/4885ADORA1 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.